Efficacy of Pregabalin in Childhood Refractory Partial Seizure by Zamani, Gholamreza et al.
 
 
* Corresponding Author; 
 Address: Children's Medical Center Hospital, 62 Qarib St, Keshavarz Blvd, Tehran 14194, Iran 
 E-mail: a_tavasoli@razi.tums.ac.ir 
© 2014 by Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, All rights reserved. 
Iran J Pediatr; Vol 24 (No 1), Feb 2014 
Published by: Tehran University of Medical Sciences (http://ijp.tums.ac.ir) 
 
Efficacy of Pregabalin in Childhood Refractory Partial Seizure 
Gholamreza Zamani1, MD; Alireza Tavasoli*1, MD; Ameneh Zare-Shahabadi2;, MD;                                             
Nima Rezaei2,3, MD, PhD; Alireza Ahmadvand4, MD 
1Department of Pediatric Neurology, 2Research Center for Immunodeficiencies, Pediatrics Center of Excellence, 
Children's Medical Center, 3Department of Immunology, Molecular Immunology Research Center; 4Department of 
Health, Tehran University of Medical Sciences, Tehran, Iran  
Received: Apr 09, 2013; Accepted: Dec 08, 2013; First Online Available: Jan 26, 2014 
Abstract 
Objective: About one third of partial seizures are refractory to treatment. Several anticonvulsant 
drugs have entered the market in recent decades but concerns about intolerance, drug 
interactions, and the safety of the drug are notable. One of these new anticonvulsants is 
pregabalin, a safe drug with almost no interaction with other antiepileptic drugs. 
 Methods: In this open label clinical trial study, pregabalin was used for evaluation of its efficacy 
on reducing seizure frequency in 29 children suffering from refractory partial seizures. 
Average daily and weekly seizure frequency of the patients was recorded during a 6-week period 
(baseline period). Then, during a period of 2 weeks (titration period), pregabalin was started 
with a dose of 25-75 mg/d, using method of flexible dose, and was brought to maximum dose of 
drug that was intended in this study (450 mg/d) based on clinical response of the patients and 
seizure frequency. Then the patients were given the drug for 12 weeks and the average 
frequency of daily and weekly seizures were recorded again (treatment period). 
Findings: Reduction in seizure frequency in this study was 36% and the responder rate or 
number of patients who gained more than 50% reduction in seizure frequency was 51.7%. 
Conclusion: This study showed that pregabalin can be used with safety and an acceptable efficacy 
in treatment of childhood refractory partial seizures. 
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Introduction 
Epilepsy is one of the most common chronic 
neurologic disorders, affecting an estimated 50 
million people worldwide (or about 1-2% of 
population). A significant proportion of neurologic 
disabilities is related to epilepsy and its associated 
conditions. Partial seizures are seen more 
frequently than generalized type in both pediatric 
and adult populations[1]. 50% of children with 
partial seizures are controlled with first 
medication. Using a second anti-epileptic drug, the 
success rate reaches about 60-70%. So about 30% 
of partial seizures, are difficult to control 
(refractory epilepsies)[2,3]. In selected patients, 
surgical treatment may be curative but overall, 
Original Article Iran J Pediatr Feb 2014; Vol 24 (No 1), Pp: 100-104 
  
101 Zamani Gh, et al 
Iran J Pediatr; Vol 24 (No 1), Feb 2014 
Published by: Tehran University of Medical Sciences (http://ijp.tums.ac.ir) 
 
there is no unique strategy for treatment of all 
epileptic patients, and yet medical treatment with 
anti-epileptic drugs is the main focus of 
therapeutic plans[4,5]. Drug-resistant epilepsy is 
associated with cognitive and behavioral problems 
and impaired psychosocial development in 
addition to increasing risk of injury and even 
death caused by recurrent seizures[6].  
     The management of epilepsy should be towards 
complete control of seizures with respect to 
minimizing the occurrence of adverse effects of 
drugs and improving the patient’s quality of life[4]. 
Pregabalin (Lyrica™) is one of the latest additions 
in the antiepileptic medication regimen that is 
structurally similar to Gabapentin. It was 
approved by Food and Drug Administration in 
USA, 2005, as an add-on therapy for partial 
epilepsy, post-herpetic neuralgia, and 
fibromyalgia. Controlled clinical trials 
demonstrated its effectiveness on peripheral and 
central neuropathic pain, and in the treatment of 
generalized anxiety disorder[4-7]. This drug crosses 
the blood-brain barrier, and binds potently to the 
α2-d subunit, an auxiliary protein associated with 
voltage-gated calcium channels in the central 
nervous system, attenuating depolarization-
induced Ca2+ influx in nerve terminals that results 
in decreasing the level of the excitatory 
neurotransmitter, glutamate, noradrenaline and 
substance P (Fig. 1)[2,6]. 
     Its pharmacological and pharmacokinetic 
profiles such as highly predictable and linear 
pharmacokinetics across the dose range (150–600 
mg/day) with low inter-subject variability, rapid 
and extensive absorption following oral dosing 
with peak plasma concentrations occurring 
approximately 1 h after oral intake and steady 
state being achieved within 24–48 h following 
repeated administration, provide a consistent and 
predictable basis for its use in clinical practice as 
an add-on antiepileptic agent[2]. This 12-week, 
open label study adds to the accumulating 
evidence of the efficacy and safety of pregabalin as 
an adjunctive treatment for refractory partial 
seizures[8-13]. No regional data evaluating the use 
of pregabalin in Iranian epileptic patients have 
been published so far. Herein, the results of a 
clinical trial on usage of pregabalin for the 
treatment of children with severe drug-resistant 
partial epilepsy are presented. 
Subjects and Methods  
Study Design 
This 12-week, open-labeled, before-after study of 
pregabalin as adjunctive treatment for refractory 
partial seizures was conducted from June 2011 to 
March 2012, in the Children's Medical Center 
Hospital, Pediatrics Center of Excellence, Tehran. 
The study protocol was approved by the 
Institutional Review Board. All patients provided 
written informed consent before entering the 
study. This study was conducted in compliance 
with the Declaration of Helsinki and the 
International Conference on Harmonization Good 
Clinical Practice Guidelines. This study was also 
registered in the Iranian Registry of Clinical Trials. 
The study comprised three main phases; after 
selecting the patients and before the onset 
treatment, in a period of 6 weeks (baseline phase), 
average daily and weekly seizures were recorded 
by the patient, a trained observer or a legal 
guardian in a diary pad. After that, during a period 
of 2 weeks (dose-optimization phase), drug was 
started with a flexible dose of 25-75 mg/d tid or of 
2 weeks (dose-optimization phase), drug was 
started with a flexible dose of 25-75 mg/d tid or 
bid and then reached a maximum dose of 450 
mg/d, based on clinical response of the patient. In 
the next 12 weeks (observation phase) the patient 
was given the drug and the average daily and
                                   
Fig. 1: Schematic presentation of pregabalin action on voltage-
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weekly patient's seizures were recorded again. 
Patients were seen at treatment weeks of 2, 4, 8 
and 12 and the rate of seizures and adverse events 
of drug were assessed. The outcome of this study 
was decrement of the patient's seizure frequency 
by 50%, compared to the baseline period. In 
flexible dose method, there is no requirement to 
increase the daily dose of patient’s drug to 
maximum dose of 450 mg/d, if fifty percent 
reduction in seizure frequencies can be achieved 
with lower doses of the drug. 
Patients 
Patients aged ≤18 years with a diagnosis of partial 
seizures as defined by the International League 
against Epilepsy (ILAE) Classification of Seizure 
(1981) were eligible for this study if the seizure 
was not adequately controlled by one to three 
AEDs administered as monotherapy or in 
combination before entering the study. All 
patients with a minimum of 4-6 partial seizures in 
the baseline phase of the study that never had a 
maximum of 28 free seizure days were included. 
     Exclusion criteria included renal failure, current 
treatment with Vigabatrin or Felbamate, having 
absence seizure, status epilepticus, Lennox 
syndrome, myoclonic seizure, neurometabolic or 
progressive neurologic disorder. 
Statistical Analysis 
Efficacy analyses used an intent-to-treat 
population (n=29) that included all patients who 
received at least 1 dose of assigned treatment. 
Seizure rate during the treatment period was 
calculated on a last observation carried forward 
(LOCF) basis. 
     The RRatio is defined as [(T-B)/(T+B)]-100, 
where B=Baseline Seizure Rate and T=Treatment 
Seizure Rate. The RRatio allows for a 
‘‘symmetrized’’ percent change with a range of       
-100 to 100. Negative values of the RRatio 
represent an improvement in seizure rate and 
positive values indicate a worsening of seizure 
rate. Therefore the zero number shows no change 
in seizure frequency and -33 shows fifty percent 
reduction in seizure frequency. The main target of 
this study was RRatio of -33 in patients. The 
RRatio approaches normality, allowing for the use 
of parametric statistics, and facilitates seizure 
subtype analyses. For ease of clinical 
interpretation, a percentage change of seizure 
reduction was derived from the RRatio values as 
follows: ([200*RRatio]/[100-RRatio]). This 
parameter is more tangible for physicians because 
it specifically shows response rate and percent 
reduction in seizure frequency of patients. This 
analysis was performed using an analysis-of 
variance model with treatment as main effect and 
rank of the RRatio as the dependent variable. 
     The major outcome variable was comparing 
fixed dose of pregabalin and the routine 
treatment. Secondary efficacy measures included 
percent changes, and changes from baseline were 
evaluated by Mann Whitney U test and Wilcoxon 
Signed Rank Test, comparing the difference to 0. 
Findings 
Twenty nine children (15 boys and 14 girls) with 
age range of 1.3 to 17.5 years (mean: 8.35±0.89 
years) with severe drug-resistant partial epilepsy 
were included in this study. There was positive 
family history of epilepsy in 51.7% of the cases; 
20% had febrile seizure. The frequency of labor 
and prenatal problems was 55.2%; the most 
prevalent ones were asphyxia (5 cases), early 
rupture of amniotic sac (3 cases), intracerebral 
hemorrhage and meconium aspiration (each one 2 
cases), hyperbilirubinemia, prematurity, neonatal 
seizure and TORCH insults (one case for each). 
     79.3% of patients had symptomatic epilepsy 
and the rest was idiopathic. Patients reported 
using 1 (3.4%), 2 (34.5%), or ≥3 (62.1%) 
concomitant AEDs during the study. Six (20.7%) 
patients had a psychiatric disorder (ADHD, anxiety 
disorder, autism behavioral disorder, depression) 
simultaneously. The most common concomitant 
AEDs in respect to frequency were Valproic acid, 
Carbamazepine, Phenobarbital, and Topiramate. 
The initial dose of Pregabalin was 25-75 mg/d and 
maximum dose450 mg/d. The mean dose of the 
drug was 70 mg/d in the initiation and 225 mg/d 
at the end. 93.7% of patients had a complete 
exposure. Only 2 (6.3%) patients left the study 
because of unsatisfying results. 
     The side effects were vertigo (10.3%), ataxia 
(6.9%), more than 7% weight gain (31%), 
drowsiness (24%) and blurred vision (3.4%). One 
case had drooling and one had agitation, which
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Table 1: Frequency of pregabalin complications 
Complication N0 (%) 
Dizziness 3 (10.3) 
Ataxia 2 (6.9) 
Weight gain 9 (31) 
Somnolence 7 (24) 
Blurred vision 1 (3.4)  
Others (drooling, irritability) 2 (6.9) 
 
were mild to moderate and reduced gradually 
during treatment (Table 1). 
     The RRatio was -32.5, this indicates 36% 
reduction in seizures frequency. Responder rate 
(percent of patients with 50% reduction in seizure 
frequency) was 51.7%. Percent changes and 
changes from baseline was significant (P<0.0001). 
Distribution of responder rate between patients 
with positive and negative family history was 
equal (P<0.290); also no significant difference in 
the distribution of responder rate between 
symptomatic and idiopathic seizures was detected 
(P<0.511), but there was significant difference in 
distribution of this variable between genders 
(P<0.046). 
Discussion 
Based on ILAE classification in 1981, generalized 
and partial seizures are two major types of 
epilepsy. Although there is good information 
about epilepsy, information about the various 
causes of refractory partial seizures is not 
enough[14]. Surgical treatment may be the 
treatment of choice in some patients, but the 
major axis of therapeutic plans is the use of 
different AEDs aimed at reducing seizure 
frequency in patients. In recent years the field of 
manufacturing AED has increased. This study 
indicated that daily administration of pregabalin is 
highly effective and well-tolerated as add-on 
therapy for controlling refractory partial seizures 
in children. With regard to other studies on 
efficacy of new anti-epileptic drugs, pregabalin has 
acquired the second place in performance and 
efficacy to help patients suffering from refractory 
partial seizures[10]. It should be noted that most of 
the new antiepileptic drugs are used as adjuvant 
or add-on therapy in treatment of drug resistant 
partial seizures. In this study, we also used 
pregabalin as add-on therapy in children with 
refractory partial seizures to reduce seizure 
frequency. Pregabalin has not a wide spectrum 
activity against different types of seizures and 
therefore should not be used for treatment of 
generalized seizures or Lennox-Gastaut 
syndrome[14]. The RRatio was -32.5 which 
indicates 36% reduction in frequency. As the 
responder rate shows, 51.7% of patients had 50% 
reduction of seizures. Carreno et al observed a 
responder rate of 52% and 39.6% at 6 and 12 
months, respectively[13]. In other studies, the 
responder rate was 31.3% and 40% for a 
pregabalin flexible dose regimen[2,8,15]. 
     As in current study, we used flexible dosing 
regimen to enhance tolerability of pregabalin as 
well as achieving efficacy to simulate general 
practice adjustment of dosage for each individual 
patient[2]. The treatment initiated with the 
effective starting dose of 25-75 mg/day followed 
by an opportunity for stepwise dose adjustment 
for those patients requiring increased doses to 
optimize efficacy and tolerability. The maximum 
dose was 450 mg/day. 
     Pregabalin appears safe, the adverse effects are 
predominantly dose-related that are associated 
with the CNS complications such as dizziness, 
ataxia, and somnolence. Despite the relatively high 
frequency of adverse effects, particularly at higher 
doses, they infrequently result in discontinuation, 
and often are transient resolving in the first few 
weeks of treatment[7,9,14,15] . 
     On the other hand, adverse effects of anti-
epileptic drugs are a particular concern in 
epileptic patients which have high frequency and 
strong association with poor health-related 
quality of life (HRQOL)[16-18]. Therefore, AEDs with 
a favorable side effect profile are of utmost 
importance to the optimal management of 
epilepsy particularly in an add-on setting as 
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multidrug treatment increases the risk of toxicity. 
In the present study, most side effects were mild 
to moderate in intensity leading to discontinuation 
in none of patients.  
     Our research is limited by the short observation 
period and, most importantly, by the lack of a 
control group, which limits the extent to which the 
results can be generalized. ‘‘Real world’’ studies 
such as this provide useful insight into the use of 
pregabalin in typical clinical situations especially 
in children as we have lack of international 
pediatric data, for example there is no mention of 
a standard dose of this drug in children in 
academic resources. 
Conclusion 
The results of this 12-week, open-label study 
extend the findings of previous studies to the local 
Iranian population, which suggest efficacy for 
pregabalin in the treatment of children with 
refractory partial seizures. This was evidenced by 
statistically significant reductions in seizure 
frequency in patients. Pregabalin was generally 
well tolerated and the safety profile was 
comparable to previously reported studies. 
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